Sarissa Capital Management’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

Sarissa Capital Management’s Portfolio NVLN Stock Details NVLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,025,000	Closed	-$3.03M	–	11
2018 Q3	$3.03M	Hold	1,025,000	–	–	0.67%	7
2018 Q2	$3.77M	Hold	1,025,000	–	–	0.76%	8
2018 Q1	$3.59M	Hold	1,025,000	–	–	0.83%	8
2017 Q4	$3.2M	Hold	1,025,000	–	–	0.82%	9
2017 Q3	$7.21M	Hold	1,025,000	–	–	2.22%	6
2017 Q2	$9.46M	Hold	1,025,000	–	–	3.16%	5
2017 Q1	$11M	Hold	1,025,000	–	–	4.35%	4
2016 Q4	$8.63M	Buy	+1,025,000	New	+$9.08M	2.38%	5

Other funds holding NVLN

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

HVC

Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

HCM

Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

DMK

David M. Knott $275M AUM 59.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sarissa Capital Management's NVLN Position: Q4 2018 in Review

Sarissa Capital Management sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q4 2018, closing a stake of 1,025,000 shares — an estimated $3.03M sold.

Sarissa Capital Management first reported a position in NVLN in Q4 2016 and held it in 8 quarters. The position peaked at $11M in Q1 2017. 36 funds tracked by Wall St. Rank hold NVLN as of Q4 2018.

Sarissa Capital Management reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q4 2018 after selling out during the quarter.
Sarissa Capital Management sold 1,025,000 Novelion Therapeutics Inc. Common Shares shares in Q4 2018, an estimated $3.03M.
Sarissa Capital Management first reported a position in Novelion Therapeutics Inc. Common Shares in Q4 2016 and held it in 8 quarters.
Sarissa Capital Management's Novelion Therapeutics Inc. Common Shares position peaked at $11M in Q1 2017.
36 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q4 2018.

Based on Sarissa Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.